Postmenopausal hyperandrogenism: the under-recognized value of inhibins.
We report a 70-year-old female presenting with increased libido and mild but rapid onset virilism. Investigations showed markedly elevated androstenedione and 17 hydroxyprogesterone misdirecting to possible late-onset congenital adrenal hyperplasia. High serum testosterone and oestrogens with suppressed gonadotrophins, however, indicated an androgen-secreting tumour. A normal dehydroepiandrosterone sulphate and elevated inhibins A and B indicated the tumour was ovarian in origin, which was confirmed on pelvic examination and imaging. At laparotomy, a right ovarian sertoliform endometrioid carcinoma was removed, following which the patient developed menopausal vasomotor symptoms and improvement of her virilism. Serum testosterone, oestradiol, inhibins A and B became undetectable, gonadotrophins appropriately increased and 17 hydroxyprogesterone and androstenedione normalized. We propose that inhibins may be of diagnostic value and should be included in investigative algorithms of females with virilization and hyperandrogenaemia, especially if postmenopausal. Androgen-secreting tumours must be excluded before raised 17 hydroxyprogesterone concentrations are used to diagnose late-onset congenital adrenal hyperplasia in females with new-onset virilization.
1 Department of Clinical Chemistry, New Cross Hospital, Wolverhampton, UK.
Jasmin L
JL
Shearer
2 Department of Histopatholgy, New Cross Hospital, Wolverhampton, UK.
Nabeel
N
Salmons
3 Department of Gynaecology, New Cross Hospital, Wolverhampton, UK.
Damian J
DJ
Murphy
1 Department of Clinical Chemistry, New Cross Hospital, Wolverhampton, UK.|4 Research Institute, Healthcare Sciences, Wolverhampton University, Wolverhampton, UK.
Rousseau
R
Gama
D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D000311:Adrenal Glands / Q000378:metabolism; D000368:Aged; D000735:Androstenedione / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D018269:Carcinoma, Endometrioid / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000601:surgery; D004958:Estradiol / Q000097:blood; D005260:Female; D006062:Gonadotropins / Q000097:blood; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood / Q000175:diagnosis* / Q000209:etiology / Q000601:surgery; D007265:Inhibins / Q000097:blood*; D010051:Ovarian Neoplasms / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000601:surgery; D017698:Postmenopause; D013739:Testosterone / Q000097:blood; D014770:Virilism / Q000097:blood / Q000175:diagnosis* / Q000209:etiology / Q000601:surgery
D014408:Biomarkers, Tumor; D006062:Gonadotropins; C422362:inhibin A; C422364:inhibin B; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D007265:Inhibins; D019326:17-alpha-Hydroxyprogesterone
Cancer; steroid hormones; tumour markers